Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allarity Therapeutics Inc

0.9586
+0.05576.17%
Post-market: 0.9500-0.0086-0.90%19:59 EDT
Volume:935.53K
Turnover:865.38K
Market Cap:4.25M
PE:-0.03
High:0.9789
Open:0.9100
Low:0.8720
Close:0.9029
Loading ...

BRIEF-Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission

Reuters
·
13 Mar

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures

MT Newswires Live
·
13 Mar

Allarity Therapeutics: Consented, Without Admitting or Denying SEC's Findings, to Entry of Administrative Cease-and-Desist Order

THOMSON REUTERS
·
13 Mar

Allarity Therapeutics Announces Final Settlement With the U.S. Securities and Exchange Commission

THOMSON REUTERS
·
13 Mar

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

GlobeNewswire
·
13 Mar

Allarity announes Phase 2 trial of stenoparib with temozolomide

TIPRANKS
·
06 Mar

Allarity Therapeutics: Announces Phase 2 Trial of Stenoparib in Combination With Temozolomide for Recurrent Small Cell Lung Cancer

THOMSON REUTERS
·
06 Mar

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

GlobeNewswire
·
06 Mar

BRIEF-Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program

Reuters
·
03 Mar

Allarity announces board authorization of $5M share repurchase program

TIPRANKS
·
03 Mar

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

THOMSON REUTERS
·
03 Mar

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

GlobeNewswire
·
03 Mar

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

THOMSON REUTERS
·
26 Feb

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

GlobeNewswire
·
26 Feb

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

THOMSON REUTERS
·
24 Feb

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

GlobeNewswire
·
24 Feb